GTI-2040. Lorus Therapeutics.

@article{Orr2001GTI2040LT,
  title={GTI-2040. Lorus Therapeutics.},
  author={Rosanne M Orr},
  journal={Current opinion in investigational drugs},
  year={2001},
  volume={2 10},
  pages={1462-6}
}
  • Rosanne M Orr
  • Published 2001 in Current opinion in investigational drugs
Loris Therapeutics (formerly GeneSense Therapeutics) is developing the antisense oligonucleotide GTI-2040, directed against the R2 component of ribonucleotide reductase, for the potential treatment of cancer [348194]. It is in phase I/II trials [353796] and Lorus had anticipated phase II trials would be initiated in July 2001. By August 2001, GTI-2040 was undergoing a phase II trial as a monotherapy for the potential treatment of renal cell carcinoma, and was about to enter a phase II… CONTINUE READING